U.S. markets closed

Cell MedX Corp. (CMXC)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.3000+0.0100 (+3.45%)
At close: 3:51PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2900
Open0.3200
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.2901 - 0.3200
52 Week Range0.2000 - 0.7990
Volume222,243
Avg. Volume79,414
Market Cap17.817M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.0160
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Cell MedX Corp. Signs Extension Agreement with Think Ink Marketing
    Newsfile

    Cell MedX Corp. Signs Extension Agreement with Think Ink Marketing

    Carson City, Nevada--(Newsfile Corp. - September 24, 2020) - Cell MedX Corp. (OTCQB: CMXC), Cell MedX Corp. ("Cell MedX" or the "Company"), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general health and wellness, announced today that it has signed an extension agreement with Think Ink Marketing Data & Email Services, Inc. ("Think Ink") to provide public relations services in an effort to increase public ...

  • Cell MedX Corp.'s eBalance Pro System Receives Class II Medical Device License from Health Canada
    Newsfile

    Cell MedX Corp.'s eBalance Pro System Receives Class II Medical Device License from Health Canada

    Carson City, Nevada--(Newsfile Corp. - September 1, 2020) - Cell MedX Corp. (OTCQB: CMXC), ("Cell MedX" or the "Company"), a bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general health and wellness, is happy to announce that in August 2020, Health Canada granted Cell MedX (Canada) Corp., the Company's wholly-owned subsidiary, a Class II Medical Device License for its innovative eBalance Pro System. ...

  • Cell MedX Corp. Closes Non-Brokered Private Placement Financing
    Newsfile

    Cell MedX Corp. Closes Non-Brokered Private Placement Financing

    Carson City, Nevada--(Newsfile Corp. - August 4, 2020) - Cell MedX Corp. (OTCQB: CMXC), ("Cell MedX" or the "Company"), a bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general health and wellness, is pleased to announce that on July 30, 2020, the Company closed its non-brokered private placement offering (the "Offering") at a price of $0.25 per unit (the "Unit"), by issuing 988,000 Units for total ...